loadpatents
name:-0.015196084976196
name:-0.013149976730347
name:-0.00059103965759277
Van Vlijmen; Herman Patent Filings

Van Vlijmen; Herman

Patent Applications and Registrations

Patent applications and USPTO patent grants for Van Vlijmen; Herman.The latest application filed is for "anti-cd154 antibodies".

Company Profile
0.13.13
  • Van Vlijmen; Herman - Somerville MA
  • Van Vlijmen; Herman - Mechelen N/A BE
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Anti-CD154 antibodies
Grant 8,961,976 - Van Vlijmen , et al. February 24, 2
2015-02-24
Methods for identifying inhibitors against viruses that use a class I fusion protein
Grant 8,898,047 - Roymans , et al. November 25, 2
2014-11-25
Anti-cd154 Antibodies
App 20140220031 - Van Vlijmen; Herman ;   et al.
2014-08-07
Humanized Antibodies Against Monocyte Chemotactic Proteins
App 20140079697 - DE FOUGEROLLES; Antonin R. ;   et al.
2014-03-20
Anti-CD154 antibodies
Grant 8,647,625 - Van Vlijmen , et al. February 11, 2
2014-02-11
Humanized antibodies against monocyte chemotactic proteins
Grant 8,519,112 - De Fougerolles , et al. August 27, 2
2013-08-27
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
Grant 8,349,324 - Lugovskoy , et al. January 8, 2
2013-01-08
Phenotype prediction method
Grant 8,285,666 - Wegner , et al. October 9, 2
2012-10-09
Cripto binding molecules
Grant 8,021,661 - Glaser , et al. September 20, 2
2011-09-20
Humanized antibodies against monocyte chemotactric proteins
Grant 7,888,479 - De Fougerolles , et al. February 15, 2
2011-02-15
Methods For Identifiying Inhibitors Against Viruses That Use A Class I Fusion Protein
App 20110009408 - Roymans; Dirk Andre Emmy ;   et al.
2011-01-13
Fc Gamma Receptor-binding Polypeptide Variants And Methods Related Thereto
App 20100203046 - van Vlijmen; Herman ;   et al.
2010-08-12
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
Grant 7,678,371 - Lugovskoy , et al. March 16, 2
2010-03-16
Phenotype Prediction Method
App 20100049689 - Jorg; Wegner Kurt ;   et al.
2010-02-25
Cripto binding molecules
App 20100008906 - Glaser; Scott ;   et al.
2010-01-14
Altered polypeptides, immunoconjugates thereof, and methods related thereto
App 20090258420 - van Vlijmen; Herman ;   et al.
2009-10-15
Anti-Cd154 Antibodies
App 20080305116 - Van Vlijmen; Herman ;   et al.
2008-12-11
Altered antibodies having improved antigen-binding affinity
App 20070135998 - Van Vlijmen; Herman ;   et al.
2007-06-14
Detecting protein similarity
App 20070088506 - Singh; Juswinder ;   et al.
2007-04-19
Fcgamma receptor-binding polypeptide variants and methods related thereto
App 20060275283 - van Vlijmen; Herman ;   et al.
2006-12-07
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
App 20060258852 - Lugovskoy; Alexey Alexandrovich ;   et al.
2006-11-16
Molecular model for VLA-4 inhibitors
Grant 6,552,216 - Singh , et al. April 22, 2
2003-04-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed